Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

The Trump administration has proposed cutting a $56 million grant that teaches first responders how to use the lifesaving ...

ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray) 1mg in the US, providing a new option ...

The US Food and Drug Administration (FDA) has approved Atzumi, a 5.2 mg dihydroergotamine (DHE) nasal powder, for the acute ...

The Trump administration has proposed terminating a $56 million annual grant program that distributes naloxone, also known by ...

Courtesy Lowenthal For decades, people suffering life-threatening allergic reactions had to quickly and correctly give ...

Discover AQST's growth potential with Anaphylm's FDA approval by Q2'25 targeting $1B revenue. Learn DCF valuations offering ...

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making ...

For five years, the clinical-stage pharmaceutical company has developed Enbumyst, a nasal spray intended to remove excess ...